F&P Healthcare ‘returned to trajectory of growth’ 

AUCKLAND, New Zealand – Fisher & Paykel Healthcare has reported total operating revenue of $1.74 billion for the 2024 financial year, a 10% increase year over year, or 8% in constant currency. 

The company says its growth was driven by solid demand in hospital consumables and strong growth in the obstructive sleep apnea mask business. 

“After several years of changing demand patterns, we are pleased to have returned to a trajectory of growth,” said CEO Lewis Gradon. “All the right foundations are in place for future success – we have an impressive portfolio of products, strong relationships with our customers and the right infrastructure to meet our future needs.” 

Specifically for the Homecare product group, F&P reported revenue of $652.3 million, an 18% increase, or 16% in constant currency. Growth was driven by the continued success of the F&P Evora Full mask in both North America and Europe. 

In its financial results, F&P also highlighted the launch of two new masks: the F&P Solo and the F&P Nova Micro. The F&P Solo, which is already available for sale in New Zealand, Australia and the United States, enables automatic fitting for patients who prefer to fit the mask without assistance. The F&P Nova Micro, which has been released in New Zealand and Canada and which is expected to launch in Australia, Europe and the United States in the 2025 financial year, was designed for patients who want to fit the mask manually. 

For the 2025 financial year, F&P expects operating revenue in the range of approximately $1.9 billion to $2 billion and net profit after tax in the range of approximately $310 million to $360 million.